Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Medigene Immunotherapies GmbH has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 3 distinct examiners. Although there are multiple examiners involved, all matters are concentrated within 1 distinct art unit, suggesting a specific technical focus for the pending applications within the USPTO classification system.
BUNNER, BRIDGET E is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. With 3 pending office actions and 3 distinct examiners, the company's workload is distributed across several individuals. However, the fact that all 3 distinct examiners are located within 1 distinct art unit may lead to a more uniform interpretation of patentability requirements compared to portfolios spread across multiple units. The 1 busiest examiner pending office action is one of the 3 pending office actions for the company.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUNNER, BRIDGET E | 1 | 64.6% | +19.8% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.4% |
| BUTTICE, AUDREY L | 1 | 46.6% | +26.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17625380 | MAGEA10 SPECIFIC T CELL RECEPTORS AND THEIR USE | ALLEN, MARIANNE P | 17d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028025 | PRAME SPECIFIC T-CELL RECEPTORS AND USES THEREOF | BUTTICE, AUDREY L | 97d overdue |
| 17625380 | MAGEA10 SPECIFIC T CELL RECEPTORS AND THEIR USE | ALLEN, MARIANNE P | 17d overdue |
| 18289801 | COMBINATION OF PRAME SPECIFIC T CELL RECEPTORS AND CHIMERIC CO-STIMULATORY RECEPTORS | BUNNER, BRIDGET E | — |
| Art Unit | Apps |
|---|---|
| 1647 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18289801 | COMBINATION OF PRAME SPECIFIC T CELL RECEPTORS AND CHIMERIC CO-STIMULATORY RECEPTORS | BUNNER, BRIDGET E | 1647 | §103DP | Non-Final OA | — | Pending | Nov 07, 2023 |
| 17625380 | MAGEA10 SPECIFIC T CELL RECEPTORS AND THEIR USE | ALLEN, MARIANNE P | 1647 | §103§112 | Final Rejection | 17d overdue | Pending | Jul 27, 2023 |
| 18028025 | PRAME SPECIFIC T-CELL RECEPTORS AND USES THEREOF | BUTTICE, AUDREY L | 1647 | §112 | Final Rejection | 97d overdue | Pending | Mar 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMedigene Immunotherapies GmbH has 3 pending office actions as of October 2026, spread across 1 art units and 3 examiners.
Bridget E Bunner has the most, with 1 of Medigene Immunotherapies GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
